mAb

Study: Deal terms getting richer as pharmas stockpile antibody tech
Fierce Biotech
Tue, 11/8/11 - 11:06 am
antibodies
autoimmune disease
CNS
Roche
AstraZeneca
Bristol-Myers Squibb
Novartis
Pfizer
Merck
mAb